Annual Review of Pharmacology and Toxicology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Circadian Regulation of Drug Responses: Toward Sex-Specific and Personalized Chronotherapy
Annu Rev Pharmacol Toxicol. 2023 Sep 18. doi: 10.1146/annurev-pharmtox-051920-095416. Online ahead of print.ABSTRACTToday's challenge for precision medicine involves the integration of the impact of molecular clocks on drug pharmacokinetics, toxicity, and efficacy, toward personalized chronotherapy. Meaningful improvements of tolerability and/or efficacy of medications through proper administration timing have been confirmed over the past decade for immunotherapy and chemotherapy against cancer, as well as for commonly used pharmacological agents in cardiovascular, metabolic, inflammatory, and neurological conditions. Expe...
Source: Annual Review of Pharmacology and Toxicology - September 18, 2023 Category: Drugs & Pharmacology Authors: Francis A L évi Alper Okyar Eva Hadadi Pasquale F Innominato Annabelle Ballesta Source Type: research

Deciphering Drug Targets and Actions with Single-Cell and Spatial Resolution
Annu Rev Pharmacol Toxicol. 2023 Sep 18. doi: 10.1146/annurev-pharmtox-033123-123610. Online ahead of print.ABSTRACTRecent advances in chemical, molecular, and genetic approaches have provided us with an unprecedented capacity to identify drug-target interactions across the whole proteome and genome. Meanwhile, rapid developments of single-cell and spatial omics technologies are revolutionizing our understanding of the molecular architecture of biological systems. However, a significant gap remains in how we align our understanding of drug actions, traditionally based on molecular affinities, with the in vivo cellular and ...
Source: Annual Review of Pharmacology and Toxicology - September 18, 2023 Category: Drugs & Pharmacology Authors: Zhengyuan Pang Benjamin F Cravatt Li Ye Source Type: research

Novel Immunopharmacological Drugs for the Treatment of Allergic Diseases
Annu Rev Pharmacol Toxicol. 2023 Sep 18. doi: 10.1146/annurev-pharmtox-051623-091038. Online ahead of print.ABSTRACTThe exponential rise in the prevalence of allergic diseases since the mid-twentieth century has led to a genuine public health emergency and has also fostered major progress in research on the underlying mechanisms and potential treatments. The management of allergic diseases benefits from the biological revolution, with an array of novel immunomodulatory therapeutic and investigational tools targeting players of allergic inflammation at distinct pathophysiological steps. Prominent examples include therapeuti...
Source: Annual Review of Pharmacology and Toxicology - September 18, 2023 Category: Drugs & Pharmacology Authors: Ekaterini Tiligada Daria Gafarov Maria Zaimi Joana Vitte Francesca Levi-Schaffer Source Type: research

Molecular Activation of NLRP3 Inflammasome by Particles and Crystals: A Continuing Challenge of Immunology and Toxicology
Annu Rev Pharmacol Toxicol. 2023 Sep 14. doi: 10.1146/annurev-pharmtox-031023-125300. Online ahead of print.ABSTRACTParticles and crystals constitute a unique class of toxic agents that humans are constantly exposed to both endogenously and from the environment. Deposition of particulates in the body is associated with a range of diseases and toxicity. The mechanism by which particulates cause disease remains poorly understood due to the lack of mechanistic insights into particle-biological interactions. Recent research has revealed that many particles and crystals activate the NLRP3 inflammasome, an intracellular pattern-...
Source: Annual Review of Pharmacology and Toxicology - September 14, 2023 Category: Drugs & Pharmacology Authors: Qiang Ma Chol Seung Lim Source Type: research

Translational In Vivo Assays in Behavioral Biology
Annu Rev Pharmacol Toxicol. 2023 Sep 14. doi: 10.1146/annurev-pharmtox-051921-093711. Online ahead of print.ABSTRACTThe failure of preclinical research to advance successful candidate medications in psychiatry has created a paradigmatic crisis in psychiatry. The Research Domain Criteria (RDoC) initiative was designed to remedy this situation with a neuroscience-based approach that employs multimodal and cross-species in vivo methodology to increase the probability of translational findings and, consequently, drug discovery. The present review underscores the feasibility of this methodological approach by briefly reviewing,...
Source: Annual Review of Pharmacology and Toxicology - September 14, 2023 Category: Drugs & Pharmacology Authors: Sarah L Withey Diego A Pizzagalli Jack Bergman Source Type: research

Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease
Annu Rev Pharmacol Toxicol. 2023 Sep 14. doi: 10.1146/annurev-pharmtox-040323-031929. Online ahead of print.ABSTRACTSleep is essential for human well-being, yet the quality and quantity of sleep reduce as age advances. Older persons (>65 years old) are more at risk of disorders accompanied and/or exacerbated by poor sleep. Furthermore, evidence supports a bidirectional relationship between disrupted sleep and Alzheimer's disease (AD) or related dementias. Orexin/hypocretin neuropeptides stabilize wakefulness, and several orexin receptor antagonists (ORAs) are approved for the treatment of insomnia in adults. Dysregulati...
Source: Annual Review of Pharmacology and Toxicology - September 14, 2023 Category: Drugs & Pharmacology Authors: Jarrah O-Z J Kron Ryan J Keenan Daniel Hoyer Laura H Jacobson Source Type: research